Conditions: Healthy Volunteers Hepatic Insufficiency Diabetes Mellitus, Type 2
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 35
Healthy volunteers: yes

Brief summary:
The primary purpose of this study is to help answer the following research questions:

* To evaluate how much of the study drug (LY2605541) is in the blood of participants with varying degrees of liver impairment compared to those with normal liver function
* To assess the safety of LY2605541 and any side effects that might be associated with it

Detailed description:
The study is conducted in 4 groups, based on the Child-Pugh classification of hepatic impairment as follows:

Group 1: Participants with normal hepatic function (Control); Group 2: Participants with mild hepatic impairment (Child-Pugh class A); Group 3: Participants with moderate hepatic impairment (Child-Pugh class B); and Group 4: Participants with severe hepatic impairment (Child-Pugh class C).

Arms:
arm 1: Participants with normal hepatic function will receive a single subcutaneous (SC) dose of 0.075 milligrams per kilogram (mg/kg) LY2605541 arm 2: Participants with mild hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541 arm 3: Participants with moderate hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541 arm 4: Participants with severe hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541

Interventions: intervention 1: LY2605541
Intervention descriptions: intervention 1: None

Protocol document: